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Pathobiologic and Metabolic Aspects of
Mammary Gland Tumorigenesis by
N-Substituted Aryl Compounds
by D. Malejka.Giganti*t, C. L. Rittert and
C. N. Ryzewskit
Metabolic or synthetic N-hydroxylation of N-arylamides yields N-arylacylhydroxamic acids consi-
derably more carcinogenic for the rat mammary gland than the parent amides both by systemic and
topical administration. The size of the aryl moiety, the position of the nitrogen relative to the aryl
moiety and the type of acyl group are determinants of the carcinogenic potency of N-arylacylhy-
droxamic acids. Induction of mammary tumors required ovarian hormones. Receptors for estrogen,
androgen and progesterone were shown in the N-hydroxy-N-2-fluorenylacetamide (N-OH-2-FAA)in-
duced mammary carcinoma. This tumor involved epithelial and stromal components of the mam-
mary gland that were separated in culture and produced tumors of their respective origin in the iso-
logous host. Both mammary epithelial cells and fibroblasts are capable of metabolism of carcino-
gens. The enzymes potentially involved in metabolic activation of N-arylamides and N-
arylacylhydroxamic acids in the mammary gland include: a cytochrome P-450(P,-450) system, UDP-
glucuronyltransferase, N,O-acyltransferases and peroxidases. Mammary microsomes in which cyto-
chrome P,-450 was induced generated small amounts of N-OH-2-FAA from 2-FAA. N-OH-2-FAA and
its carcinogenic isomer, N-OH-3-FAA, were oxidized by cytochrome c/H202 to the nitroxyl free radi-
cals which dismutated to the respective acetate esters and nitrosofluorenes. The addition of unsat-
urated lipid to either the free radicals or to the nitrosofluorenes gave electron spin resonance sig-
nals characteristic of immobilized radicals. It is proposed that interactions of carcinogens with lip-
ids and with DNA play a role in mammary tumorigenesis.
N-Hydroxylation of N-Arylamides:
A Requirement for Mammary
Gland Tumorigenicity
Mammary tumorigenesis by N-substituted aryl
compounds has been intensely studied in the rat,
the most susceptible species. Enhancement of carci-
nogenic activity by N-hydroxylation ofN-arylamides
was clearly demonstrated in immature female rats
(Table 1). The examples include the N-hydroxy me-
tabolites of N-2-fluorenylacetamide (2-FAA) and of
N-4-biphenylacetamide (4-BPAA), discovered and
tested 20 years ago by the Millers and co-workers
(1, 2) and synthetic compounds obtained and tested
by Gutmann and co-workers (3, 4). Metabolism of
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the N-arylamides and synthetic N-hydroxylation
yielded hydroxamic acids with greater carcinogenic
potency for the rat mammary gland. The size and
shape of the aryl moiety was a determinant of its
potency since the fluorenyl compounds even at
lower doses were more carcinogenic than the bi-
phenylyl compounds. The N-phenyl series was
shown to be much less, if at all, carcinogenic (3). The
type of N-acyl moiety also affected carcinogenic ac-
tivity, since the N-formyl and N-propionyl com-
pounds in the biphenylyl series were less carcino-
genic than the N-acetyl compound (5). The effect of
the position of nitrogen relative to the N-aryl moi-
ety was also determined (Table 2) (3, 6-8). Although
differences in the carcinogenicities of 2-FAA and N-
hydroxy-2-FAA could be detected at about 6
months after administration (Table 1), these com-
pounds produced similarly high incidences of mam-
mary tumors when assessed 12 months after admin-
istration (6). In contrast to 2-FAA, the structural iso-
mers, 1-, 3- and 4-FAA were weakly, if at all, carci-MALEJKA-GIGANTI, RITTER AND RYZEWSKI
nogenic (3, 7, 8). N-Hydroxylation of 3-FAA and, to a
lesser extent, of 1-FAA yielded hydroxamic acids
with increased carcinogenicities for the rat mam-
mary gland (3); however, N-hydroxylation of 4-FAA
did not increase its carcinogenicity (7). In subse-
quent metabolic studies (Table 3) we showed that
the weakly carcinogenic 3-FAA was notN-hydroxyl-
ated by the liver of the female rat in vivo (9) or in
vitro (10). In contrast, substantial amounts of carci-
nogenic 2-FAA were converted to N-hydroxy-2-
Table 1. Carcinogenicities ofN-arylamides vs. N-arylacylhydroxylamines for the rat mammary gland after systemic administration.a
F(Fluorenyl) seriesa 4 BP (Biphenylyl) seriesb _ T
Tumor Tumor
Compound R incidence Compound R incidence
2-FAA -NH-CO-CH3 5/26b 4-BPAA -NH-CO-CH3 3/16b
26/18b 10/16b
N-OH-2-FAA -NH-CO-CH3 12/12c N-OH-4-BPAA -N-CO-CH3 9/30d
17/29d
OH OH
2-FBS -NH-SO2-C6H5 1/12c 4-BPBS -NH-SO2-C6H5 1/12C
N-OH-2-FBS -NH-SO2-C6H5 12/12c N-OH-4-BPBS -NH-SO2-C6H5 5/llc
OH OH
7-OH-2-FAA 0/boe N-OH-4-BPFA -N-CO-H 2/28d
OH
N-OH-7-OH-2-FAA 6/12e N-OH-4-BPPA -N-CO-CH2CH3 6/30d
OH
aAbbreviations: 2-FAA = N-2-fluorenylacetamide; N-OH-, 7-OH- and N-OH-7-OH-2-FAA = N-hydroxy-, 7-hydroxy- and N-
hydroxy-7-hydroxy-N-2-fluorenylacetamide; 2-FBS = N-2-fluorenylbenzenesulfonamide; N-OH-2-FBS = N-hydroxy-N-2-
fluorenylbenzene-sulfonamide; 4-BPAA = N-4-biphenylylacetamide; N-OH-4-BPAA = N-hydroxy-N-4-biphenylylacetamide; 4-
BPBS = N-4-biphenylylbenzenesulfonamide; N-OH-4-BPBS = N-hydroxy-N-4-biphenylylbenzenesulfonamide; N-OH-4-BPFA = N-
hydroxy-N-4-biphenylylformamide; N-OH-4-BPPA = N-hydroxy-N-4-biphenylylpropionamide.
b12 IP injections at a dose level of 0.2 (F-series) (1) or 0.3 (BP-series) (2) mmole/kg of body weight.
c12 IP injections at a dose level of 0.1 (F-series) or 0.2 (BP-series) mmole/kg of body weight (3).
d8 IP injections at a dose level of 0.1 mmole/kg of body weight (5).
e12 IP injections at a dose level of 0.2 mmole/kg of body weight (4).
Table 2. Carcinogenicities of isomeric N-fluorenylacetamides vs. N-fluorenylacetohydroxamic acids for the rat mammary gland after
systemic administrationa
N-Fluorenylacetamides
Tumor
N-Fluorenylacetohydroxamic acids
Tumor
Isomer incidenceb Isomer incidenceb
1-FAA 4/12 N-OH-1-FAA 8/12 (12)
2-FAA 11/12 (79) N-OH-2-FAA 12/12 (80)
3-FAA 3/12 N-OH-3-FAA 12/12 (63)
4-FAA 1/13c N-OH-4-FAA 0/12
a12 IP injections at a dose level of0.1 mmole/kg ofbody weight(3, 6, 7).
bNumbers in parentheses are the percent ofmalignant tumors in the mammary gland.
CO.025% in diet for 13.3 months (8).
Table 3.N-Hydroxylation of 2-FAA and 3-FAA by the female rat.
N-Hydroxylation (%)
Pretreatment Substrate In vivoa In vitrob
2-[914C]FAA 17.3 1.72
3-MC 4.89
3-[G3H]FAA 0.03 0.01
2-FAA 0.05 0.02
aBiliary excretion of the N-hydroxy metabolite after one IP injection of the substrate (9).
bBy hepatic microsomes (10, 11).
a3-MC = 3-methylcholanthrene.
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FAA (9, 11). Hence, we postulated that only those
arylamides that are metabolically converted to hy-
droxamic acids are carcinogenic for the rat mam-
mary gland.
Metabolic Capacity of Mammary
Mixed Function Oxidase in
Relation to Tumorigenesis
We investigated whether or not N-hydroxylation
of 2-FAA also occurs in the mammary gland. In rat
liver, N-hydroxylation, as well as hydroxylations at
carbon atoms of the florene moiety, is catalyzed by
microsomal cytochrome P450, in particular by the
3-methylcholanthrene (3-MC)inducible cytochrome
P1-450 (9, 12-14). However, detection of cytochrome
P-450 or P1-450 in the mammary gland was
technically difficult (11, 15) due to the presence of
hemoglobin and mitochondrial cytochrome aa3 in the
microsomes (16). Hemoglobin was removed by
washing microsomes with hypotonic buffer (17).
Spectral interference by cytochrome aa3 was
eliminated by anaerobic reduction prior to the
reduction of cytochrome P-450 (PI-450) which was
then complexed with carbon monoxide (16). With im-
proved assay conditions, we were able to detect 1
pmole of cytochrome P-450 and 14 pmole of cyto-
chrome P,-450/mg of protein in mammary micro-
somes of corn oil- and 3MC- or p-naphthoflavone ((3-
NF)treated lactating rats, respectively (Table 4).
The levels of cytochrome P-450 and P,450 in hepatic
microsomes were about 500- and 100-fold greater,
respectively, than in mammary microsomes. Micro-
somes of both tissues were capable of hydroxylating
benzo(a)pyrene (B[a]P) and 2-FAA. The amounts of
the hydroxy metabolites of these two carcinogens
were substantially increased by pretreatment of lac-
tating rats with 3-MC or p-NF. In the liver the mag-
nitude of induction of the hydroxylating activities
was independent of the dose of inducer since three
injections of 20 or 40 mg compound/kg of body
weight gave similar increases (16). However, in the
mammary gland, induction of hydroxylating enzyme
activities was greater after treatment of lactating
rats with the larger doses of inducers. The stage of
lactation had no effect on the magnitude of induc-
tion since similar increases were observed with
treatments from the fourth through fourteenth day
of lactation, Hydroxylations of benzo(a)pyrene and 2-
FAA induced by 3-methylcholanthrene or 3-naph-
thoflavone in both hepatic and mammary micro-
somes were inhibited by 0.1 mM a-naphthoflavone
(a-NF) in vitro. The a-NF had no significant effect on
basal hydroxylating activities (16). Because a-NF is
an inhibitor of cytochrome Pl-450-dependent aryl hy-
drocarbon hydroxylase in hepatic microsomes (18),
we concluded that the increased hydroxylating
activities of mammary microsomes were indeed
cytochrome P,-450-dependent.
In more recent experiments, we determined the
level of each metabolite of 2-FAA formed by mam-
mary microsomes ofP-NF-treated lactating and non-
lactating (50-day-old) female rats using high perfor-
mance liquid chromatography (19, 20). Mammary mi-
crosomes from f3-NF-treated lactating rats had a
Table 4. Microsomal and mitochondrial enzymes of mammary gland and liver of lactating rats.
Mammary gland Liver
Enzymea Corn oil P-NFb Corn oil P-NFb
Microsomesc
Cytochrome P-450 (P,-450) 1.3 + 0.8 13.9 + 6.1 533± 191 1046 + 161
NADPH-cytochrome c reductase 18.8 + 3.2 18.1 ± 2.0 160 + 90 203 ± 82
Cytochrome b5 19.7 ± 9.6 27.1 ± 10.2 362± 74 440 ± 76
NADH-cytochrome c reductase 27.6 ± 11.4 31.6 ± 13.0 1310 ± 437 1418 ± 652
NADH-K3Fe(CN)6 reductase 779 + 212 759 ± 233 5350 ± 1336 4884± 1249
Total heme 44.4 ± 25.1 180± 77 1181± 183 1620±+ 184
Mitochondriad
Cytochrome aa3 125 ± 17 133 ± 21 66 ± 6 52± 16
Cytochrome b 47 ± 10 80± 32 212± 50 177 ± 30
Cytochrome cc, 58 ± 16 96 ± 37 140± 14 145± 17
Cytochrome c oxidasec 667 ± 100 638 ± 306 435 ± 244 640 ± 175
aThe units for cytochromes and total heme are in pmole/mg protein. The units for other enzymes are in nmole substrate (reduced or
oxidized)/mg protein/min.
bp-NF, 40 mg/kg ofbody weight, in corn oil was injected IP on days 5 through 7 oflactation.
cThese enzyme assays were described previously (16).
dMitochondrial fractions were suspended in 0.25 M sucrose, 0.025 M Tris-Cl buffer, pH 7.4, to 5 mg/mL protein and were clarified
with 1% desoxycholate. Cytochrome c (cc,) and aa3 were determined from change in absorbance AA 550-540 nm (E = 19/mM cm)
and 605-630 nm (E = 16/mM cm), respectively, of the difference spectrum of 6 M antimycin A-treated and 7.4 jM PES, 7.5 mM suc-
einate, 20 mM ascorbate reduced minus 86 M K3Fe(CN)6 oxidized complex. Cytochrome b was calculated from the increase in ab-
sorbance at 562-575 nm (E = 25.7/mM cm) upon addition of dithionite to the reduced sample.
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higher metabolic capacity than those of nonlactating
rats (Fig. 1). This may be explained by enzymatic
changes associated with the initiation and mainte-
nance of lactation in the rat mammary gland (21, 22).
Mammary microsomes of lactating rats metabolized
2-FAA to 7-, 5- and 3-hydroxy-2-FAA, as well as to 9-
hydroxy- and N-hydroxy-2-FAA. However, no de-
tectable amounts of N-hydroxy-2-FAA were formed
by mammary microsomes of nonlactating rats in
which 9-hydroxy-2-FAA was a major metabolite.
Comparison of 2-FAA-metabolizing capacities of
mammary and hepatic microsomes of the induced
lactating and nonlactating rats clearly shows that
the liver is the chief site of metabolism of 2-FAA
and of its activation via N-hydroxylation (Table 5).
The critical role of hepatic metabolism is supported
by the results of our earlier studies with disulfiram
which inhibited hepatic N-hydroxylation of 2-FAA,
thereby reducing its tumorigenicity in the mam-
mary gland (23). In lactating rats, N-hydroxy-2-FAA
produced by mammary microsomes could poten-
tially be excreted in milk contributing to tumori-
genicity in the suckling young. In preliminary
studies, we found that IP administration of 2-FAA
to lactating rats produced low to moderate tumor
incidences in both male and female offspring (D.
Malejka-Giganti and R. E. Rydell, unpublished ex-
periments). The lack of capacity of mammary micro-
somes from 50-day-old female rats toN-hydroxylate
2-FAA may explain its weak carcinogenicity on di-
rect application to the mammary gland (11, 24). It
was found in two independent laboratories that 2-
FAA, carcinogenic on systemic administration, was
only marginally active after one topical administra-
tion, whereas N-hydroxy-2-FAA was strongly car-
cinogenic (Table 6). As expected from metabolic
studies (Table 3), a weak systemic carcinogen, 3-
FAA, was only marginally active after topical appli-
cation. In contrast, its hydroxamic acid, N-hydroxy-
3-FAA, was considerably more potent (Table 6).
Hormone Responsiveness and
Cellular Composition of
Mammary Tumors
Induction of mammary gland tumors by N-hy-
droxy-2-FAA and N-hydroxy-3-FAA was dependent
on the presence of ovarian hormones in the host.
Ovariectomized rats did not develop tumors, and ad-
ministration of estrogen starting one week after
ovariectomy did not restore carcinogenicity of the
hydroxamic acids (11). The observed relationship be-
tween hormone responsiveness and the presence of
hormone receptors in some endocrine tumors
prompted us to analyze the N-hydroxy-2-FAA-in-
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FIGURE 1. HPLC analyses of metabolites of 2-FAA formed
by mammary microsomes ofP-NF-treated female rats. Sep-
arations were carried out on a 150 x 4.6 mm ID Zorbax C8
column with a 35.4 mm ID guard column of Perisorb RP-2
operated at 30°C and a flow rate of 2 mL/min. The mobile
phase contained DMSO (9.5%, v/v), isopropanol (18%, v/v),
tetrahydrofuran (1.5%, v/v), 0.5 M sodium chloroacetate,
pH 3.0 (10%, v/v) and acetohydroxamic acid (1.25%, w/v)
(19). A Varian Instruments Liquid Chromatograph, Model
5060, and a UV-50 variable-wavelength detector were
used. When 2-[9'4C]FAA (1.35 mCi/nmole) was used as the
substrate, the eluate was collected in scintillation vials
every 10 sec for the first 10 min and then every 15 sec for
the remaining 15 min. A 10-mL portion of scintillation li-
quid was added to each vial and the radioactivity was de-
termined using Tri-Carb Liquid Scintillation Spectrome-
ter, Model 3255.
I
I
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Table 5. Metabolites of 2-FAA formed by mammary and hepatic microsomes ofP-NF-treated female rats.
Source Metabolites of 2-FAA, nmole/6.0 mg protein ± S.D.b
of 7-OH- 9-OH- 5-OH- 3-OH- 1-OH- N-OH-
Rata microsomes 2-FAA 2-FAA 2-FAA 2-FA 2-FAA 2-FAA 2-FAA
Nonlactating Mammary 0.130± 0.127 0.581 + 0.20 0.155± 0.042 -c 0.360± 0.111
gland
Liver 33.1 ± 0.13 5.98± 0.30 33.2 + 0.52 2.29 + 1.53 26.5± 0.62 0.378 + 0.110 7.78 ± 1.22
Lactating Mammary 2.26 ± 0.17 0.144 ± 0.016 3.00 ± 0.60 - 2.34 ± 0.70 - 0.282 ± 0.161
gland
Liver 38.2 2.35 7.89 1.79 35.9 1.49 3.79 0.95 27.3 1.05 0.303 0.088 9.15± 0.25
ap-NF (40 mg/kg of body weight) in corn oil was injected IP on days 48 through 50 of age or on days 5 through 7 of lactation.
bMammary or hepatic microsomes, 6.0 mg protein in a total of 5.0 mL 0.1 M potassium phosphate buffer, pH 7.4, were incubated
with 200 nmole 2-FAA in 0.1 mL methanol for 30 or 10 min, respectively; NADPH, 4.2 nmole, and 5.0 mL 1 M sodium acetate were
added to start and to end the reaction, respectively. The control incubation mixtures contained heat-inactivated microsomes. The
mixtures were extracted twice with diethyl ether, the combined either extracts washed with water and evaporated to dryness un-
der a stream of nitrogen. The residues were dissolved in methanol and analyzed by HPLC (Fig. 1). Metabolite quantitation was by
peak area determination relative to standard curves. The values were corrected for losses encountered during extraction.
cThe limit of detection was 0.053 to 0.075 nmole of metabolite in the extract of the incubation mixture dissolved in 25 j1L metha-
nol of which 10,L was analyzed by HPLC.
Table 6. Carcinogenicities ofN-fluorenylamides vs.
N-fluorenylacetohydroxamic acids for the rat mammary gland
after one topical application.
Dose, Total no.
Compound jmole/no. Tumor of tumors
of glands incidence at the site
2-FAA 20/3 3/18 3 (3)a
N-OH-2-FAA 13/19 13 (9)
3-FAA 2/18 2(1)
N-OH-3-FAA 15/18 34 (6)
2-FAA 15/6 3/25 1 (1)
N-OH-2-FAA 15/27 15 (13)
N-OH-2-FAA 12/27 11 (6)
N-OH-2-FPA 9/27 8 (3)
aNo. of malignant tumors in parentheses.
duced mammary adenocarcinoma. We found recep-
tors for estrogen, androgen and progesterone; the
progesterone receptor content was increased 8-fold
after treatment of ovariectomized rats with diethyl-
stilbestrol (25). The sedimentation values, the associ-
ation constants of cytoplasmic hormone receptor
complexes, and the levels of estradiol and proges-
terone receptors were comparable to those of mam-
mary carcinomas induced by 7,12-dimethyl-
ben(a)anthracene (DMBA) or by methylnitrosourea.
The level of 5-a-dihydrotestosterone receptor in the
N-hydroxy-2-FAA-induced tumor was twice that in
the methylnitrosourea-induced tumor, but was con-
siderably lower than the level of 7S androgen
binder in the DMBA-induced tumor. The most prom-
inent difference between the carcinoma induced by
N-hydroxy-2-FAA and those induced by the other
compounds was the absence of significant amounts
of glucocorticoid receptor. This finding may be use-
ful in studies of receptor interactions, e.g., those in
which glucocorticoid binding would interfere with
that of synthetic progestins.
With cell culture we showed that mammary ade-
nocarcinoma induced in the rat with N-hydroxy-2-
FAA involved epithelial and stromal cells of the
mammary gland (26). Malignant transformation of
both cell types was confirmed by induction of the
respective tumor types after inoculation of sub-
cloned cells into isologous hosts. Our findings are
consistent with those of current studies showing
that tumors have a heterogeneous cellular composi-
tion (27). Therefore, it will be necessary to assess
the role of each type of cell in a target tissue in car-
cinogen metabolism and activation and to determine
if intercellular regulation of metabolic activities oc-
curs. Recent reports indicate that both cell types,
rat mammary epithelial cells and mammary fibro-
blasts grown in vitro, metabolized B[a]P (28, 30).
However, the levels of basal aryl hydrocarbon hy-
droxylase activity and the patterns of its inducibil-
ity by various agents in vitro differed in the two
cell types.
Activation of
N-Arylacylhydroxamic Acids to
Ultimate Carcinogens
The mechanism by which N-hydroxy-2-FAA and
other N-arylacylhydroxamic acids initiate tumori-
genesis in the rat mammary gland is under investi-
gation in several laboratories. Conversion to an elec-
trophile is still considered the probable mechanism
for activation of N-hydroxy-2-FAA. In theory, elec-
trophilic species in the rat mammary gland may be
generated from N-hydroxy-2-FAA via an intramo-
lecular N-O-acetyltransfer catalyzed by N-O-acyl-
transferase, one-electron oxidation to the nitroxyl
radical catalyzed by a peroxidase/peroxide system,
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or conjugation to N-O-glucuronide catalyzed by
UDP-glucuronyltransferase (31). Activation of N-hy-
droxy-2-FAA via all three mechanisms occurs to a
significant extent in the livers of species susceptible
and nonsusceptible to hepatocarcinogenesis (32-34).
Therefore, carcinogenicity does not appear to be de-
termined solely by these activation mechanisms. In
the susceptible mammary gland, N-O-acyltransfer-
ase-mediated activation of N-hydroxy-2-FAA and of
other related carcinogenic hydroxamic acids (Table
6) to N-acyloxyarylamines has been demonstrated
(24, 35, 36). In the case of N-hydroxy-2-FAA, the
most carcinogenic compound, this activation was in-
sensitive to paraoxon, a deacylase inhibitor (24). Ac-
tivation of the N-propionyl compound was partially
inhibited and that of the N-formyl compound was
completely inhibited by paraoxon. The mammary
gland cytosol was subsequently shown to contain
two separable enzymes, one specific for the N-acetyl
and N-propionyl compounds and the other specific
for the N-formyl compound. Since theN-formyl com-
pound induced several sarcomas in the stromal com-
ponent of the mammary gland (24), the distribution
of the two N-O-acyltransferase activities among epi-
thelial and stromal cells warrants further investiga-
tion. After administration of N-hydroxy-2-FAA to
lactating rats, a majority of adducts isolated with ri-
bosomal RNA from the mammary gland lacked the
N-acetyl group of the hydroxamic acid (36). A simi-
lar result was obtained with nonlactating rats (37).
These results indicate, although indirectly, that acti-
vation of N-hydroxy-2-FAA in the mammary gland
can occur via the N-O-acyltransferase mechanism.
Activation of the isomeric carcinogenic hydroxamic
acid, N-hydroxy-3-FAA, by this mechanism has not
been reported.
We are presently investigating one-electron oxi-
dation of the fluorenylhydroxamic acids as a possi-
ble route to electrophilic reactants in the mammary
gland. Oxidation of carcinogenic aromatic amines to
nitroxide free radicals by hepatic microsomal en-
zymes, presumably the cytochrome P450 system,
has been reported (33, 38). Since mammary micro-
somes contain a considerably less powerful mixed-
function oxidase than hepatic microsomes (16), we
looked for other cytochrome systems that might
participate in this oxidation. In contrast to the dif-
ferences in microsomal enzymes, the content of mi-
tochondrial cytochromes and the cytochrome c oxi-
dase activity were similar in the liver and mam-
mary gland (Table 6). As mentioned earlier, we
found significant amounts of cytochrome aa3, hence,
of cytochrome c oxidase activity, in mammary mi-
crosomes whose electron micrographs did not show
the presence of mitochondrial structures (16). We at-
tempted to generate nitroxide free radicals of fluor-
enylhydroxamic acids by the cytochromes present
in amounts sufficient for activity in the mammary
gland. The ESR spectra of nitroxyl radicals ofN-hy-
droxy-2-FAA and N-hydroxy-3-FAA generated by
cytochrome c and hydrogen peroxide are shown in
Figure 2. Generation of these radicals necessitated
incubation of cytochrome c with Triton X-100 and
peroxide. The nitrogen-splitting constants (8 G) and
the g values (2.0067) for the nitroxyl free radicals of
these two isomeric hydroxamic acids were similar
to each other and to the values reported for the ni-
troxide radical of N-hydroxy-2-FAA (39). The initial
N-OH-2-FAA N-OH-3 -FAA
2-NITROSOFLUORENE
G-<0_-
3-MTROSOFLUORENE
FIGURE 2. ESR spectra of nitroxyl radicals generated from
N-fluorenylacetohydroxamic acids and nitrosofluorenes. N-
OH-2-FAA or N-OH-3-FAA (a final concentration of 0.03
mM) was added in 0.02 mL methanol to 0.05 M potassium
phosphate buffer, pH 7.5, containing 0.015% (v/v) Triton X-
100 and 0.41 mg/mL of horse heart cytochrome c in a total
volume of 3.0 mL. H202 was added with stirring to give a
final concentration of 0.6 mM. The signal amplitude in-
creased with time and the spectrum was recorded at ambi-
ent temperature after about 12 min. N-OH-2-FAA, at final
concentrations of 0.03-0.33 mM, with 0.015 to 1.5% (v/v)
Triton X-100 and 0.6 mM H202 did not give a signal even
after 90 min. A Varian E-4 spectrometer with modulation
frequency of 100 KHz at an 8 G amplitude was used. The
scan rate was 20 G/min with an instrument response of 3
sec. The incident power was 20mW at a frequency of 9.442
GHz. 2-Nitrosofluorene or 3-nitrosofluorene (a final concen-
tration of 0.33 mM) was added in 0.2 mL of methanol to the
above buffer in a final volume of 3.0 mL. Hepatic micro-
somes were added to give a final protein concentration of
0.33 mg/mL. Solutions of L-a-lecithin (Sigma type V-E from
egg yolk) in chloroform: methanol were evaporated under
a stream of nitrogen and the lecithin was dissolved in buf-
fer to a final concentraion of 10 mg/mL. The spectra were
recorded after reaching maximal signal amplitudes at 16
min at ambient temperature. The instrument parameters
were as above except the scan rate was 6.25 G/min with an
instrument response time of 10 sec.
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rate of formulation of the nitroxyl free radical from
N-hydroxy-2-FAA was six times that from N-hy-
droxy-3-FAA, measured at two concentrations of
the hydroxamic acids. The radical from N-hydroxy-
3-FAA persisted for 29 min or 8 min at concentra-
tions of 0.17 mM or 0.03 mM, respectively, about
twice as long as did the radical from N-hydroxy-2-
FAA. Using thin-layer chromatography and ultravi-
olet spectroscopy, we showed that the nitroxyl radi-
cals of both isomeric fluorenylhydroxamic acids dis-
mutated to their respective acetate esters and ni-
trosofluorenes (Fig. 3) (40). Both 2- and 3-nitroso-
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FIGURE 3. Activation of N-arylacetohydroxamic acid via ni-
troxide radical.
fluorene were found to interact with double bonds
in lecithin or in hepatic microsomal lipids and
yielded ESR signals characteristic of immobilized
free radicals (Fig. 2). Similar signals were obtained
on interaction of the nitroxyl radicals with hepatic
microsomes or mitochondria. In contrast, mammary
microsomes or mitochondria rapidly quenched the
signals of added nitroxyl radicals. As yet, we do not
have a satisfactory explanation for the differences
in behavior between mammary and hepatic subcel-
lular fractions. We suspect that the lower contents
of cytochrome P450 (P1450) and of other hemes in
the mammary gland, compared to the liver, may re-
sult in the accumulation of reducing equivalents and
the consequent reduction of radicals. Work is in
progress to define conditions under which the ni-
troxyl radicals could be generated in the mammary
gland and be bound to its lipid membranes: a mech-
anism of considerable interest because of the high
lipid content of the mammary gland.
The dismutation product, 2-nitrosofluorene, inter-
acts with -SH groups on proteins to yield fluorene-
amine-adducts (Fig. 3) (41). 2-Nitrosofluorene may
also add to double bonds of lipids in an Alder-ene fa-
shion to form a hydroxylamine derivative which un-
dergoes oxidation to yield a fairly stable nitroxyl
free radical-lipid adduct (42). The other dismutation
product, an acetate ester of fluorenylhydroxamic
acid, may permanently alter DNA (43) or other mac-
romolecules (44, 45), thus affecting the transcription
process.
It is possible that both carcinogen-lipid and car-
cinogen-DNA interactions are critical in mammary
tumorigenesis. Additions of aryl-nitroso compounds
to double bonds of lipids (42) or spin-trapping of ni-
troxyl free radicals of hydroxylamines by mem-
brane components (33) may cause membrane pertur-
bations or structural membrane changes thereby af-
fecting transport. Conceivably, transport of DNA-
reactive carcinogens could be facilitated through
carcinogen-primed membranes. Furthermore, inter-
actions of carcinogens with lipids may be affected
by dietary factors which have been shown to alter
the lipid content of the mammary gland and to mod-
ify chemically induced mammary tumorigenesis in
the rat (46, 47).
Conclusions
Activation of a systemic mammary gland carcino-
gen, 2-FAA, involves its N-hydroxylation by hepatic
mixed function oxidase. Mammary mixed-function
oxidase and activation of carcinogens, e.g., N-hy-
droxylation of 2-FAA, may be induced in response
to mammary gland development or to specific envi-
ronmental factors.
Of the N-arylacylhydroxamic acids tested hereto-
fore, N-hydroxy-2-FAA is the most potent systemic
and local mammary carcinogen in the rat.
N-hydroxy-2-FAA-induced mammary adenocarci-
noma is hormone-responsive and involves epithelial
and stromal components of the rat mammary gland.
Mammary tumorigenesis by N-hydroxy-2-FAA
and related N-arylacylhydroxamic acids may in-
volve the interaction of the products of oxidative
metabolism with lipids and the interaction of the N-
acyloxyarylamine, the N-O-ester or the N-O-glucuro-
nide with DNA or chromatin.
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